Health ❯ Healthcare ❯ Pharmaceuticals

Vaccine Development

mRNA Vaccines COVID-19 Vaccines mRNA Technology COVID-19 Vaccine FDA Regulations Instituto Butantan Clinical Trials Clinical Approvals Gene Therapy Respiratory Syncytial Virus Vaccine Stocks Updated COVID-19 Vaccines Operation Warp Speed Regulatory Challenges Butantan Institute Pfizer RSV Vaccine Infectious Diseases Moderna Stock FDA Guidelines Emergency Use Authorization RSV Treatments Personalized Medicine Regulatory Oversight Hepatitis B Efluelda and Fluad New Vaccines Covid-19 Vaccines Chikungunya Vaccine Protein-based Vaccines Bavarian Nordic Immunology Cancer and Dengue Vaccines Legal Issues in Vaccination COVID-19 Therapeutics Shingles FDA Competitive Landscape FDA Approval Process Biontech and Pfizer Monoclonal Antibodies Regulatory Affairs Takeda Vaccine Vaccine Brands Takeda and Instituto Butantan Amgen Public Health Moderna and Pfizer Vaccines QDENGA

Pfizer and BioNTech Halt U.S. COVID Vaccine Trial for 50–64-Year-Olds Over Slow Enrollment

Tougher FDA rules are squeezing efforts to test shots in healthy adults 50 to 64.

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

FDA Opens Safety Review of Infant RSV Antibody Drugs Beyfortus and Enflonsia

Moderna Secures $1.5 Billion Loan, Outlines Path to 2028 Breakeven

Moderna Trims 2025 Forecast as Q3 Loss Narrows and Revenue Beats

Massachusetts Becomes First to Require Coverage of State-Recommended Vaccines

Moderna Beats Q2 Estimates But Cuts 2025 Outlook After U.K. Delay

UNM Launches Phase 1a/1b Trial of Tau-Targeting Alzheimer’s Vaccine